FAQ

ALX-0061

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2014
012320142014

Related topics

Related topics

1 relation

Broader (1)

Single-Domain Antibodies

Related mentions per year

Related mentions per year

1999-2018
1990200020102020
ALX-0061
Single-Domain Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
INTRODUCTION The pleiotropic cytokine interleukin-6 (IL-6) plays an important role in the pathogenesis of different diseases… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Review
2015
Review
2015
IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by polyarthritis. Numerous agents with varying… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2014
2014
Novartis' lung cancer ALK inhibitor approved
Regulators have backed Janssen’s first-in-class, anti-interleukin-6 (IL-6) Sylvant (siltuximab) for multicentric Castleman’s… (More)
Is this relevant?
2014
2014
Green light for Janssen's IL-6 blocker
Regulators have backed Janssen’s first-in-class, anti-interleukin-6 (IL-6) Sylvant (siltuximab) for multicentric Castleman’s… (More)
Is this relevant?
2014
2014
DBN employees charged with agricultural espionage
Regulators have backed Janssen’s first-in-class, anti-interleukin-6 (IL-6) Sylvant (siltuximab) for multicentric Castleman’s… (More)
Is this relevant?